Skip to main content
Erschienen in: International Ophthalmology 1/2016

01.02.2016 | Original Paper

Boston type 1 keratoprosthesis for failed keratoplasty

verfasst von: Jonathan L. Hager, David L. Phillips, Kenneth M. Goins, Anna S. Kitzmann, Mark A. Greiner, Alex W. Cohen, Jeffrey D. Welder, Michael D. Wagoner

Erschienen in: International Ophthalmology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to evaluate the outcomes of the Boston type 1 keratoprosthesis (Kpro-1) in eyes with failed keratoplasty. A retrospective review was performed of every patient treated with a Kpro-1 at a tertiary eye care center between January 1, 2008 and July 1, 2013. Eyes with a failed keratoplasty originally performed for corneal edema, trauma, or keratoconus were included in the statistical analysis. The main outcome measures were visual outcome, prosthesis retention, and postoperative complications. Twenty-four eyes met the inclusion criteria, including 13 eyes with corneal edema, 8 eyes with trauma, and 3 eyes with keratoconus. After a mean follow-up period of 28.9 months (range 7–63 months), the median best corrected visual acuity (BCVA) was 20/125. The BCVA was ≥20/40 in 4 (16.7 %) eyes, ≥20/70 in 9 (37.5 %) eyes, and ≥20/200 in 14 (58.3 %) eyes. Overall, the postoperative BCVA improved in 17 (70.9 %) eyes, was unchanged in 3 (12.5 %) eyes, and was worse in 4 (16.7 %) eyes. The initial Kpro-1 was retained in 22 (91.7 %) eyes, and was successfully repeated in the other 2 eyes. One or more serious prosthesis- or sight-threatening complications occurred in 8 (33.3 %) eyes. These included 1 case of wound dehiscence leading to prosthesis extrusion, 1 case of fungal keratitis leading to prosthesis extrusion, 4 cases of endophthalmitis, and 5 retinal detachments. The Boston Kpro-1 is associated with an excellent prognosis for prosthesis retention and satisfactory visual improvement in eyes with previous failed keratoplasty.
Literatur
1.
Zurück zum Zitat Thompson RW Jr, Price MO, Bowers PJ, Price FW Jr (2003) Long-term survival probability after penetrating keratoplasty. Ophthalmology 110:1396–1402PubMedCrossRef Thompson RW Jr, Price MO, Bowers PJ, Price FW Jr (2003) Long-term survival probability after penetrating keratoplasty. Ophthalmology 110:1396–1402PubMedCrossRef
2.
Zurück zum Zitat Sugar A, Tanner JP, Dontchey M, Tennant B, Schultze RL, Dunn SP, Lindquist TD, Gal RL, Beck RW, Kollman C, Mannis MJ, Holland EJ, Cornea Donor Study Investigator Group (2009) Recipient risk factors for graft failure in the cornea donor study. Ophthalmology 116:1023–1028PubMedPubMedCentralCrossRef Sugar A, Tanner JP, Dontchey M, Tennant B, Schultze RL, Dunn SP, Lindquist TD, Gal RL, Beck RW, Kollman C, Mannis MJ, Holland EJ, Cornea Donor Study Investigator Group (2009) Recipient risk factors for graft failure in the cornea donor study. Ophthalmology 116:1023–1028PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Arentsen JJ, Donoso R, Laibson PR, Cohen EJ (1987) Penetrating keratoplasty for the treatment of pseudophakic corneal edema associated with posterior chamber lens implantation. Trans Am Ophthalmol Soc 85:393–404PubMedPubMedCentral Arentsen JJ, Donoso R, Laibson PR, Cohen EJ (1987) Penetrating keratoplasty for the treatment of pseudophakic corneal edema associated with posterior chamber lens implantation. Trans Am Ophthalmol Soc 85:393–404PubMedPubMedCentral
4.
Zurück zum Zitat Pineros O, Cohen EJ, Rapuano CJ, Laibson PR (1996) Long-term results after penetrating keratoplasty for Fuchs’ endothelial dystrophy. Arch Ophthalmol 114:15–18PubMedCrossRef Pineros O, Cohen EJ, Rapuano CJ, Laibson PR (1996) Long-term results after penetrating keratoplasty for Fuchs’ endothelial dystrophy. Arch Ophthalmol 114:15–18PubMedCrossRef
5.
Zurück zum Zitat Doren GS, Cohen EJ, Brady SE, Arentsen JJ, Laibson PR (1990) Penetrating keratoplasty after ocular trauma. Am J Ophthalmol 110:408–411PubMedCrossRef Doren GS, Cohen EJ, Brady SE, Arentsen JJ, Laibson PR (1990) Penetrating keratoplasty after ocular trauma. Am J Ophthalmol 110:408–411PubMedCrossRef
6.
Zurück zum Zitat Kirkness CM, Ficker LA, Steele AD, Rice NS (1990) The success of penetrating keratoplasty for keratoconus. Eye 4:673–688PubMedCrossRef Kirkness CM, Ficker LA, Steele AD, Rice NS (1990) The success of penetrating keratoplasty for keratoconus. Eye 4:673–688PubMedCrossRef
7.
Zurück zum Zitat Pramanik S, Musch DC, Sutphin JE, Farjo AA (2006) Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology 113:1633–1638PubMedCrossRef Pramanik S, Musch DC, Sutphin JE, Farjo AA (2006) Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology 113:1633–1638PubMedCrossRef
8.
Zurück zum Zitat Yaghouti F, Nouri M, Abad JC, Power WJ, Doane MC, Dohlman CH (2001) Keratoprosthesis: preoperative prognostic categories. Cornea 20:19–23PubMedCrossRef Yaghouti F, Nouri M, Abad JC, Power WJ, Doane MC, Dohlman CH (2001) Keratoprosthesis: preoperative prognostic categories. Cornea 20:19–23PubMedCrossRef
9.
Zurück zum Zitat Zerbe BL, Belin MW, Ciolino JB, Boston Type 1 Keratoprosthesis Study Group (2006) Results from the multicenter Boston type 1 keratoprosthesis study. Ophthalmology 113:1779PubMedCrossRef Zerbe BL, Belin MW, Ciolino JB, Boston Type 1 Keratoprosthesis Study Group (2006) Results from the multicenter Boston type 1 keratoprosthesis study. Ophthalmology 113:1779PubMedCrossRef
10.
Zurück zum Zitat Aldave AJ, Kamal KM, Vo RC, Yu F (2009) The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology 116:640–651PubMedCrossRef Aldave AJ, Kamal KM, Vo RC, Yu F (2009) The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology 116:640–651PubMedCrossRef
11.
Zurück zum Zitat Chew HF, Ayres BD, Hammersmith KM, Rapuano CJ, Laibson PR, Myers JS, Jin YP, Cohen EH (2009) Boston keratoprosthesis outcomes and complications. Cornea 28:989–996PubMedCrossRef Chew HF, Ayres BD, Hammersmith KM, Rapuano CJ, Laibson PR, Myers JS, Jin YP, Cohen EH (2009) Boston keratoprosthesis outcomes and complications. Cornea 28:989–996PubMedCrossRef
12.
Zurück zum Zitat Colby KA, Koo EB (2011) Expanding indications for the Boston keratoprosthesis. Curr Opin Ophthalmol 22:267–273PubMedCrossRef Colby KA, Koo EB (2011) Expanding indications for the Boston keratoprosthesis. Curr Opin Ophthalmol 22:267–273PubMedCrossRef
13.
Zurück zum Zitat Robert MC, Harissi-Dagher M (2011) Boston type 1 keratoprosthesis: the CHUM experience. Can J Ophthalmol 46:164–168PubMedCrossRef Robert MC, Harissi-Dagher M (2011) Boston type 1 keratoprosthesis: the CHUM experience. Can J Ophthalmol 46:164–168PubMedCrossRef
14.
Zurück zum Zitat Greiner MA, Li JY, Mannis MJ (2011) Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis. Ophthalmology 118:1543–1550PubMedCrossRef Greiner MA, Li JY, Mannis MJ (2011) Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis. Ophthalmology 118:1543–1550PubMedCrossRef
15.
Zurück zum Zitat Patel AP, Wu EI, Ritterband DC, Seedor JA (2012) Boston type 1 keratoprosthesis: the New York eye and ear experience. Eye (Lond) 26:418–425CrossRef Patel AP, Wu EI, Ritterband DC, Seedor JA (2012) Boston type 1 keratoprosthesis: the New York eye and ear experience. Eye (Lond) 26:418–425CrossRef
16.
Zurück zum Zitat Aldave AJ, Sangwan V, Basu S, Basak SK, Hovakimyan A, Gevorgyan O, Kharashi SA, Jindan MA, Tandon R, Mascarenhas J, Malyugin B, Padilla MD, Maskati Q, Agarwala N, Hatauruk J, Shamra M, Yu F (2012) International results with the Boston type 1 keratoprosthesis. Ophthalmology 119:1530–1538PubMedCrossRef Aldave AJ, Sangwan V, Basu S, Basak SK, Hovakimyan A, Gevorgyan O, Kharashi SA, Jindan MA, Tandon R, Mascarenhas J, Malyugin B, Padilla MD, Maskati Q, Agarwala N, Hatauruk J, Shamra M, Yu F (2012) International results with the Boston type 1 keratoprosthesis. Ophthalmology 119:1530–1538PubMedCrossRef
17.
Zurück zum Zitat Aquavella JV, Qian Y, McCormick GJ, Palakuru JR (2005) Keratoprosthesis: the Dohlman-Doane device. Am J Ophthalmol 140:1032–1038PubMedCrossRef Aquavella JV, Qian Y, McCormick GJ, Palakuru JR (2005) Keratoprosthesis: the Dohlman-Doane device. Am J Ophthalmol 140:1032–1038PubMedCrossRef
19.
Zurück zum Zitat Wandling GR, Rauen MP, Goins KM, Kitzmann AS, Sutphin JE, Kwon YH, Alward WL, Wagoner MD (2012) Glaucoma therapy escalation in eyes with pseudophakic corneal edema after penetrating keratoplasty and Descemet’s stripping automated endothelial keratoplasty. Int Ophthalmol 32:9–14PubMedCrossRef Wandling GR, Rauen MP, Goins KM, Kitzmann AS, Sutphin JE, Kwon YH, Alward WL, Wagoner MD (2012) Glaucoma therapy escalation in eyes with pseudophakic corneal edema after penetrating keratoplasty and Descemet’s stripping automated endothelial keratoplasty. Int Ophthalmol 32:9–14PubMedCrossRef
20.
Zurück zum Zitat Dohlman CH, Dudenhoefer EJ, Khan BF, Morneault S (2002) Protection of the ocular surface after keratoprosthesis surgery: the role of soft contact lenses. CLAO J 28:72–74PubMed Dohlman CH, Dudenhoefer EJ, Khan BF, Morneault S (2002) Protection of the ocular surface after keratoprosthesis surgery: the role of soft contact lenses. CLAO J 28:72–74PubMed
21.
Zurück zum Zitat Khan BF, Harissa-Dagher M, Khan DM, Dohlman CH (2007) Advances in Boston keratoprosthesis: enhancing retention and prevention of infection and inflammation. Int Ophthalmol Clin 113(2):61–71CrossRef Khan BF, Harissa-Dagher M, Khan DM, Dohlman CH (2007) Advances in Boston keratoprosthesis: enhancing retention and prevention of infection and inflammation. Int Ophthalmol Clin 113(2):61–71CrossRef
22.
Zurück zum Zitat Ward MS, Goins KM, Greiner MA, Kitzmann SA, Sutphin JE, Alward WLM, Greenlee EC, Kwon YH, Zimmerman MD, Wagoner MD (2014) Graft survival versus glaucoma treatment after penetrating or Descemet’s stripping automated endothelial keratoplasty. Cornea 33(8):785–789PubMedCrossRef Ward MS, Goins KM, Greiner MA, Kitzmann SA, Sutphin JE, Alward WLM, Greenlee EC, Kwon YH, Zimmerman MD, Wagoner MD (2014) Graft survival versus glaucoma treatment after penetrating or Descemet’s stripping automated endothelial keratoplasty. Cornea 33(8):785–789PubMedCrossRef
Metadaten
Titel
Boston type 1 keratoprosthesis for failed keratoplasty
verfasst von
Jonathan L. Hager
David L. Phillips
Kenneth M. Goins
Anna S. Kitzmann
Mark A. Greiner
Alex W. Cohen
Jeffrey D. Welder
Michael D. Wagoner
Publikationsdatum
01.02.2016
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 1/2016
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-015-0078-2

Weitere Artikel der Ausgabe 1/2016

International Ophthalmology 1/2016 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.